in the drinking water of R6/2 mice, a commonly studied mouse model of HD. Disease progression was compared with mice on a regular diet. The mice on a cysteine-supplemented diet fared much better than mice on a regular diet. These mice were able to stay longer on a balancing wheel and gripped objects with greater strength. In addition, the cysteine-treated mice survived longer than the mice on a regular diet. Our findings establish that brain damage in HD is mediated by mutant huntingtin binding to and inhibiting SP1 thereby diminishing levels of the cysteine-forming enzyme CSE. Treatment with cysteine or related agents may be beneficial in HD. Survival and function of striatal neurons is dependent on brain-derived neurotrophic factor (BDNF), and levels of this trophic factor are significantly reduced in Huntington disease (HD) patients. Recently, strategies aimed at BDNF restoration have become a leading candidate for the treatment of HD. Transplantation of adult stem cells, such as bone marrowderived mesenchymal stem/stromal cells (MSC), show considerable therapeutic promise through stimulation of endogenous neuronal growth, decreased neuronal apoptosis, regulation of inflammation, and the secretion of trophic factors. MSC are readily available, easily expanded in vitro, have immunomodulatory properties, and can be easily engineered to overproduce trophic factors. Previously, in animal models of HD, it has been shown that allogeneic transplantations of MSC can significantly delay the onset of behavioral abnormalities and reduce the severity of neuropathological changes in both transgenic and toxic lesion models of HD. In a pivotal proof-of-concept study, transgenic mice showed significant behavioral and neuropathological sparing following the intrastriatal administration of MSC engineered to overexpress BDNF. The aim of the current study is to test the preclinical safety and efficacy of allogeneic human MSC engineered, using a lentiviral vector, to secrete BDNF (MSC/BDNF). Our product combines the beneficial effects of MSC administration with the benefits of sustained BDNF production.
These proof-of-concept and safety studies are being conducted in support of HD-Cell, a planned future phase I clinical trial designed to examine the safety and potential efficacy of MSC/BDNF. The current studies focus on the optimal transduction coefficients, the level of BDNF produced by our development candidate, the karyotypic stability of the candidate, the safety profile following transplantation in immune deficient mice, cell retention in vivo, and efficacy following transplantation in the YAC128 and R6/2 transgenic mouse models of HD, as Investigational New Drug-enabling studies for the Food and Drug Administration, in support of a future planned phase I clinical trial. Support for this project was provided by a California Institute for Regenerative Medicine (CIRM) grants no. TR1-01257 (Nolta) and DR2-05415 (Wheelock/Nolta), National Institutes of Health Director's transformative award 1R01GM099688 (Nolta), and philanthropic donors from the HD community, including the Roberson family and TeamKJ. 
Paradigm for Neuroprotection in Presymptomatic Huntington Disease
Huntington disease (HD) commences more than 20 years before clinical symptoms. A major therapeutic goal is to delay or prevent onset in those who are not yet symptomatic. We report the first therapeutic trial in presymptomatic individuals at risk for HD. We utilized high-dose creatine monohydrate, a leading candidate disease-modifying therapy for HD and a novel recruitment strategy that included premanifest individuals known to have the HD mutation and 50 % at-risk individuals who did not wish to know their genetic status. Subjects that did not have the HD mutation provided a control group for biological measures while removing the risk of coerced genetic testing. The trial consisted of a double-blind, placebo-controlled phase lasting 6 months and an unblinded open-label phase in which all subjects were followed for an additional year. Clinical, neuroimaging, and blood markers of HD were assessed longitudinally. We show that it is feasible to conduct therapeutic trials in individuals at risk for HD, that clinical and biological markers can measure progression in these subjects, and that high-dose creatine, slowed brain atrophy, beneficially impacted additional markers, and may be disease modifying in premanifest HD. Indiana University, Indianapolis, IN, USA.
In 1979, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research wrote the Belmont Report in an attempt to summarize the basic ethical principles of research with human subjects. The first principle, "Respect for Persons", speaks to the concept of autonomy. Specifically, individuals must be treated as autonomous agents capable of making independent decisions, as reflected in the process of obtaining informed consent. The second principle, "Beneficence", addresses the ethical concept embodied in the phrase "First, do no harm". In practical terms, this means the need to maximize the benefits and minimize the risks when performing research using human subjects. The third principle, "Justice", indicates that the benefits and burdens of research be equally distributed such that no particular population is unduly burdened nor excluded from the potential benefits that might result from research. This presentation will discuss these principles in the context of clinical research with those affected by and at risk for Huntington disease with an emphasis on the PHAROS and PREDICT studies, as well as clinical trials with a particular focus on the disclosure of research information. Background: Huntington disease (HD) is a neurodegenerative disorder for which neuroprotective strategies remain ineffective. The neuroprotective capability of cysteamine has been demonstrated in numerous HD animal models. Cysteamine is an approved drug to treat cystinosis, a rare genetic disorder characterized by the accumulation of cystine in different organs. Objective: To characterize efficacy and safety of cysteamine in patients with HD. Methods: This was a multicenter, double-blind, placebocontrolled trial. Inclusion criteria were age between 18 and 65 years, CAG repeats >38, and minimum score of the Unified HD Rating Scale of Total Motor Score (TMS)≥5 and Total Functional Capacity>10. Patients were randomized to receive placebo or 1200 mg/d of delayed-release cysteamine (RP103) orally. Patients were allowed to continue their baseline medication regimen. The primary endpoint was change in TMS at 18 months. Secondary endpoints included changes in functional autonomy, cognition, behavior and mood, as well as evaluation of safety. Results: Ninety-six subjects were randomized to treatment and constituted the intent to treat population. TMS progression, as determined by using a repeated-measures mixedeffect model with the 96 patients, was 33 % slower in patients treated with cysteamine than those treated with placebo (4.5 points vs 6.7, respectively; p=0.19). In a post hoc subset analysis of the per-protocol population with 66 patients not taking concurrent tetrabenazine (the approved drug for treatment of chorea in HD), cysteamine treatment resulted in a slower progression in TMS of 57 % versus the placebo group (2.8 points vs 6.5, respectively; p=0.03). No significant effects were observed in secondary endpoints. Thirty-eight patients (86 %) from the placebo group and 48 patients (92 %) receiving treatment experienced at least one adverse event; gastrointestinal complaints were most common. Conclusion: Delayed-release cysteamine (RP103) is a safe well tolerated drug that may slow progression of motor impairment in early-stage HD.
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Posters will be staffed from 8:00 -9:00 AM and 10:30 -11:00 AM in Great Lakes C. University of Ulm, Ulm, Germany. Background: Enroll-HD is an innovative clinical research platform for Huntington's disease (HD). Its foundation is a longitudinal observational study in a global cohort that collects phenotypic data and biosamples in a standardized manner across all participating centers. We report here the characteristics of the cohort and the current status of the program. Objectives: The overall goal of Enroll-HD is to function as a long-term clinical research platform that will accelerate the development of therapeutics for HD by 1) facilitating the conduct of clinical research and accelerating clinical trials, 2) better understanding HD in a global cohort, and 3) improving clinical care.
Methods: Enroll-HD is a longitudinal observational study collecting common data elements across all participating centers. Participation is open to HD gene-expansion carriers (HDGECs) who are either symptomatic or presymptomatic, untested at-risk individuals, gene-negative HD family members, and family controls (not blood-related; limited to 25 % of total enrollment per site). Data and biosamples for biobanking are collected annually on all participants. Data quality is ensured using a risk-based monitoring approach. Results: Since the first ethics committee approval (April 2012) and the first participant enrollment (July 2012), 2593 participants have been enrolled (as of 1 July 2014): 1290 (50 %) symptomatic HDGEC, 403 (16 %) presymptomatic HDGEC, 298 (11 %) at-risk (genotype unknown), 148 (6 %) gene-negative family members, and 441 (17 %) family controls. Baseline descriptive data on the cohort and an update on study start-up and implementation, including number of baseline and follow-up visits, will be presented. Conclusions: Enroll-HD is a global research platform that collects phenotypic data and biosamples from a wellcharacterized cohort. We study genetic mixture models for Huntington disease (HD) data from the Cooperative Huntington's Observational Research Trial. An important area of clinical and statistical research is properly estimating the age-atonset (AAO) distribution of HD. Such estimates provide critical information in the design of clinical trials, and assist clinicians, genetic counselors, and patients in making important medical decisions (e.g., treatments). We present a novel approach for estimating the AAO distribution of HD based on a varying-coefficient, logist i c m i x e d e f f e c t s m o d e l . O u r m e t h o d u s e s semiparametric techniques to incorporate the influence of different patient-specific features even when some feature information is missing. Our method also accommodates the family-induced correlation without the need to postulate or estimate any latent variable distributions. Finally, we handle censored observations using a jackknife estimator, which yields consistent and efficient model parameter estimates. Our method addresses several key issues in HD research: incorporating patient-specific features using a data-driven, nonparametric approach, accounting for the family-induced correlation through distribution-free random effects, and handling censored observations due to patient-dropout. Simulation results and application to the COHORT data demonstrate our method's usefulness. The Walton Centre NHS Foundation Trust, Liverpool, UK.
Background: The Enroll-HD project aims to recruit one-third of the manifest Huntington disease (HD) patients living in areas served by study sites. We conducted an audit of REG-ISTRY study participants at two sites (Manchester and Liverpool) to assess the feasibility of this, and to investigate the effect of geographical and socioeconomic factors on equality of access to the service. Aims: To determine the number of REGISTRY participants per 100,000 of the population in different areas of North West England, and the relationship of this to distance from study sites and indicators of economic deprivation. Methods: The total number of living REGISTRY participants and the number of currently active participants were calculated for each county and borough in North West England. Postcodes were used to assign subjects to census areas (lower-layer super output areas; LSOAs) and the distribution of LSOAs containing at least one REGISTRY participant was compared with the overall distribution using the Index of Multiple Deprivations of the UK Office of National Statistics. Results: Rates of current REGISTRY participation varied greatly from borough to borough, but was approximately 4/100,000 across most of the region, rising to 6/100,000 when inactive participants were included. The borough with the highest rate of participation was the most geographically distant (about 3 h travel) from the study sites. LSOAs containing a REGISTRY participant were significantly more likely to have a higher deprivation score. Conclusion: Assuming a prevalence of 10/100,000, our findings suggest the goal of recruiting one-third of available subjects is achievable. Distance from the study site was not a barrier to access in our region. Given that the primary cause of HD is genetic, the significant relationship with indices of deprivation suggests that HD has a detrimental effect on the socioeconomic status of families, as well as the health of affected individuals. PRE-CELL is a lead-in observational study for a future planned phase I cellular therapy trial in Huntington disease (HD-CELL). The primary objective is to enroll a cohort of up to 40 subjects with early stage Huntington disease (HD) to characterize clinical, neuroimaging, laboratory, and biomarker correlates of disease progression over a 12-18-month period. Subjects completing this study will be candidates for enrollment in the future planned phase I trial of intrastriatal delivery of mesenchymal stem cells (MSC)/ brain-derived neurotrophic factor (BDNF). MSC have significant neurorestorative effects, including promoting neurite outgrowth, secreting antiapoptotic and neuroprotective factors, and have immunomodulatory properties. MSC are readily available, easily expanded in vitro, and can be easily engineered to overproduce trophic factors. BDNF levels are significantly reduced in HD, and MSC engineered to overexpress BDNF have been shown to ameliorate behavioral and neuropathological findings in the YAC 128 transgenic HD mouse model. We are conducting preclinical studies in preparation for obtaining regulatory approval for a future planned phase I trial of human MSC engineered to overexpress BDNF as a potential neuroprotective therapy in patients with early-stage HD. In PRE-CELL we will prospectively collect validated quantitative clinical and neuroimaging measures of disease progression, as well as exploratory biomarkers over a 12-18-month period, which will enable us to determine the slope of change in each measure for each subject. Subjects enrolled have genetically-confirmed early-stage HD. Study visits occur every 6 months. Outcome measures will include rate of change in 1) clinical motor, cognitive, psychiatric, behavioral, and functional measures; 2) volumetric analysis of regional neuroimaging measures; and 3) serum and cerebrospinal fluid biomarkers. The rate of change in these measures for each subject will serve as a baseline to enhance the safety and permit exploratory measures of efficacy in HD-CELL. We will present clinical characteristics of subjects enrolled to date. Background: Magnetic resonance spectroscopy (MRS) allows noninvasive investigation of brain metabolism. We recently reported, using 31P MRS, that the Pi/PCr ratio increases during visual stimulation in controls, but not in patients at an early stage of Huntington disease (HD), suggesting alterations of brain energy metabolism in those patients. Objectives: 1) To measure the rate of the creatine kinase (CK) in visual cortex at rest, during visual stimulation, and during recovery using 31P MRS; and 2) to measure metabolite concentrations in visual cortex using 1H MRS. Methods: We studied 10 early HD patients (UHDRS 15±11, range 4-33) and 10 age-matched controls with 31P MRS and 1H MRS. All measurements were performed on a 3 T Siemens Trio scanner. The rate of CK was measured using 31P magnetization transfer (MT) MRS (pulse-acquire, TR 15 s) by saturating the gamma-adenosine triphosphate resonance every other scan (BISTRO saturation pulse train 3.5 s). Concentrations of metabolites were measured with a semi-LASER sequence (TE 28 ms, TR 5 s) and quantified using water as an internal concentration reference. All spectra were analyzed using LCModel. Results: 31P MT MRS: The rate of CK was similar in controls and patients at rest. During visual stimulation, however, the rate of CK was 5 % higher in controls than in patients (p <0.05). 1H MRS: There was a significant decrease in tNAA in patients versus controls (10.6 vs 11.1 mM; p <0.01), consistent with neuronal loss and cortical atrophy in patients. Conclusion: Measurement of the rate of CK using 31P MRS confirms abnormal energy metabolism in visual cortex during functional activation in early HD. This reduced CK rate could explain the lack of increase in Pi/PCr ratio during visual activation that we observed previously. Abnormal functional energy metabolism in visual cortex could potentially be used as an early indicator of treatment efficacy in prospective clinical trials. Background: PHAROS aimed to identify signs and symptoms in adults at risk for Huntington disease (HD) who have not undergone DNA testing. Suicide attempts are increased in those with HD, particularly those with depression, making accurate risk factor assessment a priority for clinicians. Objective: To characterize additional features associated with suicidal ideation (SI) in subjects at risk for HD. Methods: The Beck Depression Inventory (BDI II) was used to assess depression, and BDI II question 9 (suicidal thoughts) was used to divide subjects into those who did or did not report SI. Four additional subjects who made suicide attempts but did not report SI were included in the SI group. Hopelessness was assessed on the Beck Hopelessness Scale, impulsivity on the Barratt Impulsivity Scale, and aggression and irritability on the Unified HD Rating Scale (UHDRS). A logistic regression model adjusted for age and sex was used to explore significance of these prespecified predictors. t tests and χ 2 tests were used for unadjusted comparisons. Results: Of 455 subjects assessed, 22 were classified as having SI. Compared with subjects not exhibiting SI, SI subjects had significantly increased hopelessness (mean 4.5 vs 1.9; p=0.01), impulsivity (mean 23.7 vs 21.1; p=0.03), and aggression (41 % vs 6 %; p<0.0001), but did not differ on irritability. In the adjusted model, hopelessness, aggression, and impulsivity remained significant predictors of SI. Adjustment for HD expansion mutation carrier status, psychoactive medication use, and motor score on the UHDRS did not substantively change these results. Conclusions: Hopelessness and aggression were significantly higher in those reporting SI in subjects at risk for HD. Impulsivity, related to particularly lethal suicide attempts, is an important behavioral issue in those with brain disorders. Identification of these features could assist clinicians in assessment of suicidal behavior in this high-risk group. what is their most bothersome problem related to HD; 2) how does this problem affect their functioning; and 3) to rate severity of the problem. The HD-PROP was administered in the REACH2HD phase II randomized, placebo-controlled clinical trial assessing the safety, tolerability, and potential benefits of PBT2, an experimental modulator of metal homeostasis and neuronal activity. The trial enrolled 109 adults with HD who were assessed with the HD-PROP at baseline, 3 months, and 6 months, reporting a total of 849 bothersome problems over the 3 time points. Verbatim responses were coded by an independent neuropsychologist who classified them based on clinical experience and widely recognized features of HD. Descriptive statistics were used to analyze the most commonly reported problems and their functional consequences. Of the 64 categories of reported problems, the top 5 most bothersome problem categories were: 1) movement (10.1 %); 2) balance (9.6 %); 3) memory (8.9 %); 4) not being able to drive (5.1 %); 5) family impact/concern about HD genetic transmission (3.7 %). Of the 82 categories of reported consequences, the top 5 most commonly reported functional consequences of all problems were: 1) no consequence for daily function (11.8 %); 2) dependence on others (6.2 %); 3) taking longer to do things (5.7 %); 4) forgetfulness (5.2 %); 5) communication difficulties (4.6 %). Among the participants who reported no functional consequence, the top 5 associated most bothersome problems were movement (13.8 %), balance (7.8 %), family (7.8 %), future (6.9 %), and genetic (6.0 %). The HD PROP is a useful self-reporting research tool to capture patients' perceptions of their bothersome problems and related functional impact. Support: Prana Biotechnology (Melbourne, Australia) and the Griffin Foundation. Introduction: Unfortunately, there is very little research examining the health-related quality of life (HRQoL) issues that are most important for individuals with Huntington disease (HD). To address this, the HDQLIFE study was designed to evaluate HRQoL in individuals with HD. Objective: To examine the relationship between new selfreport measures of HRQoL (the Neuro-QoL, www.neuroqol. org; PROMIS, www.nihpromis.org) and both clinician-rated measures and other generic HRQoL measures in HD.
Design: Observational study involving 459 individuals (41 % males), between the age of 18 and 81 years (mean 49.23, SD 13.29) with a clinical diagnosis of HD (n=277), and/or a positive genetic test for HD (n=365). Clinician-rated measures included the Unified HD Rating Scale and the Problem Behaviors Assessments. Self-report measures included selected computer adaptive tests from Neuro-QoL and PROMIS, as well as several generic self-report HRQoL measures (EQ-5D, RAND-12, and WHODAS 2.0). Clinician-rated measures were completed during in-person clinic visits and all selfreport measures were collected via an online survey with the exception of the EQ-5D, which was administered as a paper form during the clinic visit. Results: Generally, PROMIS/Neuro-QoL measures had moderate correlations with clinician rated measures (r=0.33-0.70), with the majority between 0.41 and 0.61). In addition, PROMIS/Neuro-QoL had moderate-to-strong correlations with generic self-report measures of HRQOL (r=0.34-0.75). Conclusions: These results provide support for the validity of PROMIS/Neuro-QoL measures in evaluating HRQoL in HD. Furthermore, when used in conjunction with clinician-rated measures, self-report measures can provide a more comprehensive assessment of HRQOL in HD. Prospective memory (PM) is a facet of episodic memory that involves the ability to perform an intended action at some designated point in the future. Evidence suggests that PM is dependent on frontal system integrity, as well as associated executive processes known to be impaired in Huntington disease (HD). Given the role of PM in essential functional activities (e.g., taking medication at correct time), PM impairment may be a unique risk factor for declines in everyday functioning. However, to our knowledge, no study has investigated PM in this population. In the current study, 20 individuals diagnosed with mild-to-moderate HD and 20 demographically similar healthy adults completed performancebased, seminaturalistic, and self-reported PM tasks. Compared with healthy adults, HD participants demonstrated impairment on the seminaturalistic PM trial (p<0.01) and in both time-based (p<0.001) and event-based (trend level, p= 0.05) PM in the laboratory. HD participants committed significantly more "no response" errors than healthy adults on time-based trials (p<0.01) and event-based trials (p<0.05). However, there were no significant differences between groups in the number of "task substitution", "loss of content", and "loss of time" errors (all p-values>0.05). There were no significant group differences (p>0.05) on the retrospective recognition memory test. HD and healthy participants provided comparable self-reported PM complaints, suggesting that individuals with HD may have overestimated their PM abilities. These results highlight the importance of using objective assessments of PM in individuals with HD. As PM is thought to play a critical role in many everyday tasks, the current findings imply that PM deficits may be associated with everyday functioning in HD. The results may lead to the development of interventions aimed at teaching compensatory cognitive strategies for PM dysfunction to improve everyday functioning in individuals with HD.
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Instrumental Activities of Daily Living in Huntington Disease: A Performance-based and Self-report Assessment The use of self-report and proxy-report is an important limitation of prior studies examining functional decline in Huntington disease (HD). Report-based methods may yield inaccurate estimations of functional abilities due to biases such as lack of insight, depression, and cognitive impairment. The current study used a multimodal approach that included selfreport and performance-based measures to examine instrumental activities of daily living (iADLs) in HD patients. The present study examined iADLs in 20 individuals diagnosed with mild-to-moderate HD and 20 demographically similar healthy adults using both performance-based and self-report iADL measures. HD patients reported significantly reduced medication management abilities and greater declines in their ability to manage finances. On the performance-based measures, individuals with HD did not differ from healthy adults on a medication management test; however, those with HD performed significantly below healthy adults on a financial management test. Additionally, self-report and performancebased measures of ability to manage finances or medications were not significantly correlated in the HD group. The results of the current study support declines in global iADLs and specific impairment in medication management in HD. The data also suggest that individuals with HD exhibit deficits in at least some functional capacity, which was assessed with performance-based tasks (financial management). In addition, these results indicate that selfreport and performance-based measures may be assessing different aspects of iADLs and that the evaluation of HD patients' ability to perform real-world tasks may require a multimodal approach. Objective: To enhance estimates of Huntington disease (HD) onset using a simple and practical body sway assessment device (i.e., Wii Balance Board; Nintendo, Kyoto, Japan). Background: HD is a progressive neurodegenerative disorder with motor, cognitive, and psychiatric symptoms that typically emerge in the fourth or fifth decades of life. Balance assessments may be useful for predicting disease onset and progression, but studies are limited. Methods: We assessed total body sway (TBS) on 53 HD gene carriers and 25 normal controls (NC) employing a Wii balance board and laptop software. Gene carriers were categorized as 1) early premanifest; 2) transitional [i.e., individuals close to disease onset or with very mild HD: Unified HD Rating Scale Total Functional Capacity (TFC) ≥10, Total Motor Score <30, and Penney Burden of Pathology score ≥295]; or 3) later HD. Subjects were administered a balance test consisting of twelve 10-s static balance trials that included combinations of eyes open or closed while standing on a stable versus unstable (i.e., foam) surface. A one-way ANOVA with Tukey post hoc comparisons was used to compare TBS; correlations were assessed using Pearson's r. Results: Participants were well matched with regard to age and education. The later HD subjects (n=24) showed statistically significant TBS in all conditions (p<0.001) compared with NC, and even the transitional subjects (n=16) showed significantly more TBS in the eyes closed condition on an unstable surface (p=0.018), with a trend towards significance in the eyes open condition on both the stable and unstable surfaces (p=0.057 and p=0.054, respectively). TBS correlated most strongly with measures of motor ability (r=0.622-0.793) and TFC (r=-0.499 to -0.721) as opposed to cognition (r=-0.261 to -0.419). Conclusion: Increased body sway, easily evaluated using a brief balance assessment, may serve as an important functional marker in patients with, and during the transition to, HD. Further studies will be needed to confirm and extend these findings. Behavioral changes, including apathy, depression, irritability, anxiety, and difficulty prioritizing and initiating activities, are characteristic features of Huntington disease (HD). For families and caregivers, they are often the most distressing aspect of the disease. The assessment of these behavioral disturbances is therefore important. The objective of the current study was to examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, HD. The University of California San Diego (UCSD) HD Behavioral Questionnaire (HD-BQ) consists of 30 items with a 3-point rating scale (0-3), and takes about 5 mins to complete. The maximum score is 90; higher scores indicate more behavioral changes. Reliability, in addition to clinical and construct validity, were examined using data from 49 individuals with HD, 21 preHD, and 13 normal control (NC) subjects. The UCSD HD-BQ showed substantial internal consistency (Cronbach α = 0.95). It showed construct validity with strong correlations with other behavioral instruments (Problem Behaviors Assessment-Short r=0.437, p=0.042; Hospital Anxiety and Depression Scale r=0.455, p=0.044), and poor correlations with measures of cognitive functioning (MMSE r = 0.156; MOCA r = 0.156) and motor impairment (UHDRS Total Motor Score r = -0.096). The UCSD HD-BQ discriminated between HD (mean 31.14, range 1-79), preHD (mean 24.76, range 0-55), and NC (mean 5.69, range 0-12). When questionnaires were completed independently by 28 HD subject/caregiver pairs, there was a discrepancy in the perception of impairment between patients and their caregivers, with caregivers identifying more behavioral changes (mean difference= 16.17 points). In conclusion, the HD-BQ is a quick, reliable instrument for screening behavioral changes in patients with, and at risk for, HD. When possible, information regarding behavior should be corroborated by an informant as patients tend to underestimate their impairment. Further studies will be needed to confirm and extend these findings. Objective: To explore the reliability of the Motor section of the Unified Huntington Disease Rating Scale (UHDRS) conducted remotely. Background: A modified motor section of the UHDRS (mUHDRS) conducted via web-based videoconferencing is feasible; however, limited data exist on the reliability of the mUHDRS assessed remotely. Methods: Chorea, dystonia, oculomotor, and bradykinesia domains of the UHDRS conducted in-person and remotely were compared using intraclass correlation coefficients (ICC). Individual motor items conducted in-person and remotely were compared using weighted kappa coefficients (κ). These analyses were repeated comparing 2 telemedicine evaluations to determine test-retest reliability. Owing to the growing number of patients who are institutionalized, the volume of phone calls from LTC facility staff has increased. The most common phone calls received are related to movements and/or behavioral issues. In order for HD Program staff to develop an appropriate treatment plan it is important to receive an accurate description of the symptoms. Many of the LTC staff are unprepared, however, to answer detailed questions regarding HD symptoms. Objectives: To create a comprehensive and efficient tool for obtaining and documenting HD symptoms and treatment plans. A tool was developed to help facilitate LTC staff preparation and accurate descriptions of symptoms. The tool also provides an efficient means to document details of the phone consult. Methods: Two comprehensive tools were developed, one for movements and one for behavior. Common nursing assessment questions were organized into flow charts. Areas for narratives are available adjacent to each question. A section for treatment plan documentation is available at the end of the document. Results: The comprehensive tool has made detailed documentation easier and more efficient. The user reads the questions and follows the flow chart. The caller answers the questions and responses are recorded. Upon completion, it is signed and filed into the medical record. Transcriptional dysregulation has long been recognized as central to the pathogenesis of Huntington disease (HD). microRNAs (miRNAs) are a class of small noncoding RNAs that recognize sites of complementarity of target miRNAs resulting in transcriptional decay and translational repression of target genes. Dysregulation of miRNA post-transcriptional machinery may affect gene expression and influence HD pathology. Using next-generation miRNA sequence analysis in prefrontal cortex (Brodmann Area 9) of 26 HD, 2 asymptomatic HD, and 36 controls, we identified 75 differentially expressed miRNAs in HD at genome-wide significance (False Discovery Rate (FDR) p-value <0.05). Among the HD brains, 11 miRNAs were significantly associated with Vonsattel grade. Five miRNAs (miR-10b-5p, miR-196a-5p, miR196b-5p, miR-10b-3p , and miR-106a-5p) were identified as having a significant association (FDR p-value <0.05) to CAGadjusted age of onset. Three miRNAs (miR-10b-5p, miR-10b-3p, miR-302a-3p) were observed to have a significant relationship (FDR p <0.05) to CAG-adjusted Hadzi-Vonsattel striatal score, a continuous measure of striatal atrophy. These results suggest potential involvement of miRNAs to important aspects of HD pathogenicity. Recently, miRNAs have shown promise as possible biomarkers for a variety of human diseases and based upon their relationship to disease expression, these miRNAs are strong biomarker candidates in HD.
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Immune Function and Neuro-inflammation are Implicated by mRNA Transcriptomics in Huntington Disease Huntington's disease (HD) is a devastating neurodegenerative disorder that is clinically marked by loss of motor function, personality changes, and ultimately death. The disease is caused by an expanded CAG nucleotide repeat in the Huntingtin (HTT) gene and subjects usually begin presenting symptoms by the age of 40. No therapies to date have proven effective at delaying or ameliorating disease severity. Here we present a genome-wide analysis of mRNA expression in postmortem human brain tissue from HD subjects using next-generation high-throughput sequencing. Widespread gene expression changes are observed between HD and neuropathologically normal control subjects. The list of differentially expressed genes is enriched in biological processes previously implicated in HD, including immune response, transcriptional regulation, and apoptosis. A set of genes related to developmental processes not previously reported in HD is also observed. Computational analysis of transcription factors predicted to regulate DE genes identifies MAZ, FOXO1, and known Huntington protein (Htt) interacting transcription factors as enriched in HD. Markers for several major cell types are observed, suggesting that this dataset represents a tissuewide response to HD in the brain. Together, the results describe a coordinated response to mutant Htt from multiple constitutive neuronal cell types, and suggest potential novel therapeutic avenues. Although the Huntingtin gene has been extensively studied since its identification in 1993, with many proposed cellular roles, its normal function remains not well defined. Characterizing a Huntingtin homolog in Drosophila, a simple yet genetically tractable system, will complement the established mammalian models for Huntingtin studies. We established a null-mutant (dhtt-ko) for this Drosophila Huntingtin (dhtt) and performed preliminary characterization of its phenotypes. We found that expression of human Huntingtin could rescue the dhtt-ko mutant phenotypes, suggesting its evolutionally conserved functions and also supporting the use of the fruit fly to study human Huntingtin. Using this dhtt-ko mutant, we have conducted genetic modifier screens to identify cellular pathways that require the presence of normal dhtt activity. In addition, to take advantage of the abundant tools available in Drosophila for functional investigation of Huntingtin, we have developed a set of apparatuses that allows convenient detection and isolation of endogenous dHtt protein. Using Pacman and MiMIC approaches we have successfully generated and confirmed a set of genome dhtt transgenic lines with different fluorescence and epitope tags that allow convenient tracking and isolation of endogenous dHtt protein. Because the tagged dhtt gene in these established lines is still in its endogenous genomic DNA context, the expression of the tagged dhtt remains under the control of its native regulatory elements, thus ensuring the normal patterns and expression levels of the tagged dHtt protein. Using these genome-tagging lines, we have further carried out affinity purification followed by mass spectrometry from Drosophila tissues and identified large number of unique dHtt-interacting proteins. Importantly, the majority (96 %) of the isolated dHtt interactors are conserved in humans and some of them have previously been reported as Huntingtin-interacting partners from mammalian-based studies. Functionally, these Huntingtin interactors can be grouped into multiple categories. Examination of the available dataset supports that Huntingtin functions as a scaffold to integrate multiple signaling pathways and cellular processes. Following up on the results from the dhttko mutant-based genetic screens and the proteomic data from Drosophila studies, we are conducting further analyses in mammalian cells to validate the relevance of the findings to humans. By combining genetic and genomic approaches in Drosophila and mammalian systems, the knowledge learned from these studies are helping elucidate the normal functions of human Huntingtin gene and how its dysfunction due to polyglutamine expansion contribute to HD pathogenesis. Increasing evidence suggests that brain mitochondrial function is compromised in animal models of HD. However in vivo evidence is scarce. Magnetic resonance spectroscopy (MRS) has proved to be an ideal modality for nondestructive and highly detailed assessment of structural morphology and energetic status. Here, we used the novel 17O MRS technique on HD mice to determine rates of oxygen consumption for the direct measurement of mitochondrial function in vivo. The maximal rate of respiration is proportional to the concentration of the cytochrome oxidase enzyme in the electron transport reaction and can be used as a measure of mitochondrial function. To compare the energy capacity between HD mouse brains and controls, we determined the in vivo basal and maximal velocity for oxidative phosphorylation, also known as the respiration or oxygen consumption rate, CMRO2, using 16.4 tesla 17O MRS in male HD mice and littermates at 9 weeks of age. Utilizing a custom-designed oxygen delivery system and 17O MRS methodology described previously, the basal oxygen consumption rate did not differ between isoflurane anesthetized R6/2 mice and littermates. At rest, striatal CMRO2-basal of R6/2 mice was 2.49± 0.35 μmol/g/min (n = 9), while that of littermates was 2.67±0.33 μmol/g/min (n=10), indicating comparable mitochondrial output despite onset of motor symptoms in R6/ 2. CMRO2-max was tested 10 min after systemic injection of di-nitrophenol (DNP), an uncoupling agent that shunts the proton electrochemical gradient increasing complex IV activity producing maximal mitochondrial respiration. After DNP injection, the striatal CMRO2 of R6/2 mice was 2.88± 0.40 μmol/g/min, significantly less than that of littermates (3.42±0.57; p <0.05, 2-tailed t test). The reduced spare energy capacity in diseased R6/2 striatum is indicative of abnormal mitochondrial function. While these experimental conditions represent maximal energetic demand, in diseased mice, regular functional or stress-related energy demands may tax this limited mitochondrial capacity. Support: CHDI damaged organelles, and parasites. It has special relevance for Huntington's disease (HD), which is characterized by the accumulation of misfolded mutant huntingtin (mHtt). Autophagy is therefore a promising target for blunting mHtt-induced neurodegeneration. In a search for novel regulators of autophagy in neurons, we identified sphingosine kinase 1 (SK1) as a regulator of neuronal autophagy. SK1 generates sphingosine-1-phosphate, a lipid implicated in cell survival. We found that, in neurons, expression of SK1 enhanced the formation of preautophagosomal structures and increased flux through the autophagic pathway. SK1S224A mutant was not able to upregulate autophagy. Expression of a d o m i n a n t -n e g a t i v e f o r m o f S K 1 i n h i b i t e d autophagosome synthesis. In a neuron model of HD, SK1 decreased the accumulation of an aminoterminal exon 1 fragment of mHtt containing a pathogenic stretch of 46 glutamines. These results identify a novel regulator of neuronal autophagy and provide a new target for developing therapies for HD. Intranasal (i.n.) administration is a relatively novel technique to target therapeutics to the central nervous system for the treatment of neurodegenerative and other brain diseases. Rather than being released into the bloodstream, drugs administered i.n. gain direct access to the central nervous system by traveling extracellularly along the olfactory and trigeminal nerves, and via the perivascular space. The main benefits are that drugs bypass the blood-brain barrier, systemic exposure to the liver and other organs is minimal, and it is noninvasive. Several drugs in our laboratory have been delivered to rodent models of neurodegenerative disease and shown efficacy. Foremost is intranasal deferoxamine (i.n. DFO), which has shown efficacy in rodent models of Alzheimer and Parkinson diseases. In Alzheimer mouse models, i.n. DFO decreases spatial memory loss and soluble amyloid in both tau and amyloid models. In a unilateral 6-hydroxydopamine (6-OHDA) rat model of Parkinson disease, i.n. DFO decreased Parkinsonian symptoms in the drug-induced rotational and cylinder tests, and the magnitude of lesions in the medial forebrain bundle. Approval for i.n. DFO is currently being pursued for clinical trials. These studies demonstrate that i.n. administration also has potential for the treatment of Huntington disease (HD). Indeed, some studies presented at the most recent annual meeting of the Society for Neuroscience included IN treatments for rodent models of HD, and are likely to be published soon leading the way for i.n. administration of drugs for HD. Semaphorin 4D (SEMA4D) is expressed on neural and immune cells, and its high-affinity receptor, Plexin B1 (PLXNB1), is expressed on neural, endothelial, and immune cells. SEMA4D signaling through PLXNB1 modulates glial cell activation, inhibits migration and differentiation of oligodendrocyte precursor cells (OPC), disrupts central nervous system (CNS) endothelial tight junctions, and induces neuronal process collapse. Neuroinflammatory/ neurodegenerative diseases are characterized by myelin destruction and neuronal degeneration and often associated with compromise to the neurovascular unit. Antibody neutralization of SEMA4D could, therefore, ameliorate neurodegenerative disease through multiple mechanisms. Blocking SEMA4D could promote remyelination through survival, migration, and differentiation of oligodendrocyte precursors, reduce inflammation, and, by preventing SEMA4D-mediated breakdown of the blood-brain barrier (BBB), suppress immune cell infiltration into the CNS. We generated a monoclonal antibody that binds with high affinity to rodent, monkey, and human SEMA4D, and blocks Sema4D binding to its cognate receptors. In vitro, anti-SEMA4D reverses the inhibitory effects of recombinant SEMA4D on OPC survival and differentiation. In vivo, anti-SEMA4D significantly attenuates damage in neuroinflammatory and demyelinating disease by preserving BBB integrity and axonal myelination. Strikingly, in a murine transgenic model of Huntington disease (HD), antibody blockade of SEAM4D preserves brain volume and prevents some associated cognitive deficits (collaboration with Amber Southwell and Michael Hayden). Current studies suggest a broader role for glia-specific SEMA4D s i g n a l i n g m e c h a n i s m s i n n e u r o i n f l a m m a t o r y / neurodegenerative disease. Collectively, these data suggest that antibody-mediated neutralization of SEMA4D represents a novel therapeutic strategy for neurodegenerative diseases including HD and multiple sclerosis. To this end, a randomized, placebo-controlled, double-blind, single ascending dose phase 1 study in multiple sclerosis patients using a humanized anti-SEMA4D antibody (VX15/2503) will soon be completed, and enrollment in a multiple ascending dose trial in patients with HD is planned to begin in early 2105.
Poster 18 Dissect Huntingtin's Endogenous Functions Using
Poster 22
Poster 25
The Enroll-HD Care Improvement Committee: How Enroll-HD Can Improve Quality Of Care in Huntington Disease Background: ENROLL-HD is an international, prospective, longitudinal observational study of Huntington disease (HD) subjects. The objectives of the study include 1) improving our understanding of the clinical signs and symptoms and the disease mechanisms of HD; 2) fostering good clinical care and improving health outcomes; 3) enhancing the design and expediting the conduct of clinical trialsThe Care Improvement Committee (CIC) is charged with improving the care of patients with HD so that we can improve outcomes based on prospective data and evaluating best practices. Methods/Techniques: The CIC has membership from USA, Canada, Norway, Scotland, and New Zealand, and includes neurologists, neurogeneticists, nurse specialists, health services researchers, and HD family members and advocates. The first CIC project involves a survey of all ENROLL-HD sites. It will assess the clinical care models employed by different centers to better understand how HD clinical services are being delivered internationally at expert sites. Initial survey results will be presented. Based on successful quality improvement initiatives in other medical conditions like cystic fibrosis, Parkinson disease, and cardiovascular surgery, CIC will assess the effects on HD patient outcomes, initially in symptomatic patients, based on case-mix patient factors, treatment factors, and center effects. As an initial strategy the existing registry database is being analysed to identify trends and generate hypotheses. Details of the analysis plan will be presented.
Conclusions:
The primary objective of the CIC is to evaluate cross-sectional and longitudinal data obtained in ENROLL-HD in an attempt to determine best practices that are involved in improved outcomes of HD patients. This prospective, datadriven strategy is designed to provide information on how to improve outcomes and provide evidence for future patient care guidelines in HD. Study Group (HSG) will have convened in September 2014 to develop clinically relevant guides for the symptomatic treatment of anxiety, agitation, apathy, psychosis, and sleep disorder symptoms of HD. Because there is insufficient evidence base to provide guidelines from the peer-reviewed literature for any of the several behavioral symptoms related to this disease, the task force will utilize the Institute of Medicine model for the development of "trustworthy" clinical guides [1] that will be followed by a Delphi process for consensus achievement. The task force consists of 10 EHDN and HSG psychiatry and neurology specialists who have been clinicians active in both clinical care and clinical research in HD, a general medical physician, HD family representatives, and advisers from the Huntington's Disease Society of America (HDSA) and CHDI Foundation. The process includes stepwise development of statements "intended to optimize patient care" that include diagnosis, description, prevalence, prevention, treatment strategies, and prognosis domains for each symptom. Statements developed through this process will subsequently go through an iterative Delphi consensus process of a larger group of at least 50 additional experts drawn from both EHDN and HSG at the end of 2014. Publication of each of the 5 symptoms standard of care articles is anticipated by the third quarter of 2015. Funding for this project is provided by grants from the Griffin Foundation and Auspex Pharmaceuticals. Background: Trunk control impairments affecting axial movements may contribute to activity limitations and falls in individuals with Huntington's disease (HD). We examined HD trunk control using the new Level Belt Pro application that utilizes an iPod (Apple, Cupertino, CA, USA) accelerometer to examine axial movements. Methods: Forty-one individuals with HD [age 52±11 (26-70) years] and 31 matched controls [age 49.7±11.1 (21-68) years] participated. The Tinetti Mobility Test (TMT) and Unified HD Rating Scale (UHDRS) motor scale were administered, and a falls history was obtained. Participants maintained erect sitting and standing postures for 60 s each and walked 50 feet while wearing 2 iPods with Level Belt Pro software, positioned at midscapular (thoracic) and L5 (pelvic) levels using belts. Mean thoracic and pelvic excursion values in anterior-posterior and medial-lateral directions across all 3 conditions were calculated.
Results: Individuals with HD demonstrated greater anterior pelvic tilt (3.73°±4.15) and trunk extension (5.22°±8.06) in sitting (controls=.33°±5.17; 1.28°±1.05); greater anterior pelvic tilt in standing (HD =5.76°±5.20; controls=1.21°±
.88); and greater anterior pelvic tilt (HD=7.36°±5.14; controls=4.72°±2.98) and trunk flexion (HD=11.41°±6.49; controls=7.39°±3.46) in walking. Better UHDRS motor and/or TMT scores correlated moderately with greater anterior pelvic tilt and trunk flexion in standing and with greater anterior pelvic tilt and trunk flexion during walking. Falls in the last week correlated with backward trunk sway (r=0.339) in walking and posterior pelvic tilt (r=0.399) in standing. Conclusions: Trunk excursion during functional activities is significantly greater in individuals with HD compared with controls and correlates with clinical measures of mobility and falls. Level Belt Pro may be useful for examining HD truncal movements and assessing effectiveness of interventions. Introduction: Individuals with Huntington disease (HD) develop both cognitive and motor (i.e., balance and gait) deficits that become more severe over the course of the disease process. The purpose of this study was to investigate the relationship between specific cognitive measures and mobility measures across time in individuals with HD. Methods: A retrospective review of the medical records of 85 individuals with HD who attended the Ohio State University Huntington's Disease Society of America Center of Excellence between 1 January 2009 and 31 December 2013 was conducted to obtain demographic information [age, sex, Unified Huntington's Disease Rating Scale (UHDRS) motor scores, time since diagnosis], UHDRS cognitive battery scores (verbal fluency, symbol digit modality test, and stroop test), Tinetti Mobility Test (TMT) scores, and normalized gait velocity during comfortable forward walking as measured by the GAITRite system. Pearson's correlation coefficients were used to determine relationships between the mean UHDRS motor scores, cognitive scores, and mobility (TMT, gait velocity) scores. Results: Lower UHDRS motor scores indicating better function were moderately (r=0.52-0.62) related to better performance on all cognitive measures and the TMT. Higher cognitive scores were significantly related to better TMT scores with the highest correlations found between cognitive measures and TMT gait subscale scores (r=0.30-0.43). Gait velocity was not related to UHDRS motor scores or cognitive scores. Implications: Declines in gait and balance performance as measured by the TMT may reflect cognitive decline in individuals with HD. Our findings suggest that the TMT may be a useful clinical assessment for detecting mobility deficits related to cognitive dysfunction in the HD population. Information about the relationship of cognition and motor function in individuals with HD may help researchers and clinicians to develop better interventions to improve mobility in the HD population.
Poster 29 People with Huntington disease (HD) report problems with hand function. While upper limb motor impairments have been characterized, there is a lack of data on functional limitations that may result from these impairments. We examined the earliest functional limitations of the upper limb and the association of functional limitations with motor and cognitive function. Methods: Twenty healthy controls, 23 premanifest (PHD), and 20 manifest HD (MHD) subjects. Hand function was assessed using the Manual Ability Measure (MAM), a task-oriented, self-report questionnaire that contains 20 one-and two-handed functional tasks. Participants rated their function on a 5-point scale, with higher scores indicating better function. General function was evaluated with the HD-Activities of Daily Living (HD-ADL), a 17-item self-report questionnaire Items are rated on a 4-point scale (0-3) with higher scores indicating greater functional limitations. Motor function was assessed with the Unified HD Rating Scale; total motor score and cognitive function was assessed with the Stroop task. Results: Hand function (MAM) was significantly worse for PHD far from onset (p <0.01), PHD near onset (p <0.003), and MHD (p <0.0001) compared with controls. General functioning (HD-ADL) was worse for PHD close to onset (p <0.03) and MHD (p <0.001) compared with controls. Item analysis revealed that the earliest functional limitations were seen for handwriting, opening medicine bottle, wringing a towel, handling money, and cooking. MAM was significantly correlated with motor (r=-0.29, p <0.05) and cognitive function (r= 0.63, p <0.003). Conclusions: MAM is a sensitive assessment of early functional limitations in HD. The earliest functional problems were noted in tasks that either required bimanual control (wring towel, open medicine bottle) or integration of cognitive and motor skills (writing, handling/counting money, cooking). Her father died at the age of 47 in a state psychiatric hospital. Her mother died in her 80s from a bowel disorder. The patient's family reported her unique lifestyle of a high salt, high fat diet, with minimal fiber. She smoked 4 packs of menthol cigarettes a day, took vitamin E supplements, and chewed iron pills. She drank, on average, 18 cups of coffee per day and was a "social" alcohol user. The patient was able to drive until the age of 75, when she was diagnosed with glaucoma. She passed away at 86 after she sustained a subdural hemorrhage due to a slip and fall. Autopsy was performed. Results: Brain autopsy showed Vonsattel grade 0 with polyglutamine-positive staining. Although there was no classical HD histopathology in this case, polyglutamine immunohistochemistry was positive in the neocortex and neostriatum and negative in cerebellar Punkinje cells, which is consistent with HD.
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Conclusions: Even though this patient had 41 CAG repeats, she had no clinical signs or symptoms of HD and her brain biopsy did not show neuronal loss. We speculate that some aspect(s) of her unusual dietary habits were neuroprotective and prevented her from becoming symptomatic. Predictive testing programs for Huntington disease (HD) have been available in the US for over 20 years now; yet little has been published regarding the <10 % of individuals at risk for HD who actually pursue presymptomatic testing. The objective of this study was to examine the clinical characteristics and motivations of individuals choosing to undergo predictive testing at one academic site. Participants were asked to fill out a questionnaire prior to testing that explored items such as family history, social supports, reason(s) for testing, likelihood that the individual possessed a positive gene, and expected outcomes after the result. Over a 16-year period (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , a total of 164 individuals at risk for HD requested predictive testing. The mean age was 39.7 (range 19-75); 58.5 % were women. Most were white (83.3 %), married (56.8 %), and already had children prior to testing (57.7 %). More men (60.9 %) had an affected mother; more women (55.7 %) had an affected father. Most participants (67.6 %) did not have siblings who had already gone through predictive testing. Reasons for testing were evenly distributed among "family planning" (23.6 %), "know how to spend next 20 years" (20.7 %), "clarify children's status" (22.9 %), and "reduce uncertainty" (21.4 %); however, more men wanted to "know how to spend next 20 years" (29.8 %), whereas more women wanted to "reduce uncertainty" (27.7 %). Of the subjects who eventually tested positive, > 40 % felt they were likely, very likely, or certain to carry the mutation. Interestingly, of the subjects who eventually tested negative, 24 % felt that they would likely feel uncomfortable with their siblings. Almost half of all subjects felt that depression, either temporary or longlasting, might be a potential outcome. We conclude that, although predictive testing obviously helps some individuals with reproductive and life planning, the possible social and psychological consequences of pursuing presymptomatic testing should also be considered. Purpose: Approximately 1.4 million young children under the age of 20 in the USA provide some measure of care to a family member. These "young carers" experience depression, poor school performance, and problems with peers, leaving them socially isolated. Given the complicated symptoms and hereditary nature, these issues may be particularly salient to young carers of a parent with Huntington disease (HD). Indeed, the challenging symptoms of HD contribute to stigmatization and social isolation among predominately spousal caregivers, yet little is known about the experiences of children and teen "young carers". Methods: In-depth, semistructured interviews were conducted with 40 identified young carers, (9 male, 31 female) aged 12-20 years. Study participants represent 18 states, accessed through the Huntington's Disease Society of America. Results: Study participants partake in an average of 18 caregiving tasks per week, with over half providing personal care for complicated HD symptoms. Study participants experienced school problems (60 %) and conflict with parent with HD (92 %). Primary caregivers (n=10), experience significantly higher depression than young carers who share caregiving duties with other family members. While 46 % of all participants had to miss activities in order to care for their parent, two-thirds felt guilty when they were not helping out at home. Eighty-five percent of all participants reported unmet support needs. Qualitative support themes detail the need for other people to assist in caregiving tasks, and emotional support for their caregiving experience. Implications: Findings from this study suggest that young carers provide numerous caregiving duties for extended periods of time, yet have little to no support from friends and other adults. Results provide clear evidence for the acknowledgment of young carers by HD healthcare providers, and the development of support programs and interventions to meet the needs of these isolated family caregivers.
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The Role of Occupational Therapy in Caring for Individuals with Huntington Disease K. Moser. Rocky Mountain University of Health Professions, Provo, UT, USA.
Background: Huntington disease (HD) is a brain disease affecting an individual's movement, cognition, and behaviors. This results in a progressive decline of their ability to perform activities of daily living. With this overall functional decline, occupational therapy has the opportunity to play a role in the management of symptoms and the maintenance of quality of life for individuals and families affected by HD. Aim: To identify the role of occupational therapy on a multidisciplinary team caring for individuals affected by HD. Method: After a literature review on research related to occupational therapy and HD, relevant information was integrated into one comprehensive source for professionals working within the HD community. Conclusion: Occupational therapists have the skills and tools necessary to be a part of the multidisciplinary team caring for individuals with HD at any stage of the disease. Background and Objectives: The advent of the electronic health record (EHR) leads to potential new concerns about the privacy of sensitive medical information. The Huntington's Disease Society of America (HDSA) Center of Excellence at University of California (UC) Davis has seen a growing number of individuals seeking anonymous predictive testing. We sought to query a broad sample of at-risk individuals and those who have previously undergone Huntington disease (HD) predictive testing about their attitudes, beliefs, and concerns regarding predictive testing in the era of the EHR. Methods: An anonymous survey approved by the institutional review board at UC Davis was released at the 2014 HDSA national convention, posted on the HDSA website, and distributed at northern California regional HD programs and support groups. Results and Discussion: There have been 239 respondents to date. The majority were white (97.1 %), 84.1 % female, and ranged in age from 16 to 62 years, with a broad geographic representation across Northern America. Almost all (91.8 %) had health insurance, 55.4 % had life insurance, 24.9 % had disability insurance, and 15.9 % long-term care insurance. Most respondents (70.3 %) were familiar with the Health Insurance Portability and Accountability Act, while 49.8 % were familiar with the Genetic Information Nondiscrimination Act. Ninety-five respondents (40.3 %) had completed predictive testing, 22 (9.3 %) were undecided, and 119 (50.2 %) had chosen not to test. Reasons for choosing not to test varied, but 20 % indicated concerns about genetic discrimination. Factors playing a role in their decisions will be presented. More than half indicated that the option to test anonymously would be very or extremely important in decision making. For those who had completed predictive testing, 49 % chose to pay privately, and 21 % tested anonymously. Most were very satisfied with the predictive testing process and most were very confident that their privacy was maintained. Further statistical and qualitative analyses of survey responses will be presented. The University of Sydney, Sydney, Australia.
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Introduction: Antipsychotics are commonly used for management of behavioral symptoms in dementia among people in residential care. This continues to occur despite their modest effectiveness, potential harms, including increased risk of death and stroke, and absence of detrimental effect when people with dementia were randomized to antipsychotic withdrawal. This study aims to test the hypothesis that the multi-faceted REducing AntiPsychotic use in residential care: Huntington Disease (REAP-HD) program, is more effective than standard staff education (SSE) in reducing antipsychotic use for people with Huntington disease (HD) in residential care facilities (RCF). Methods and analysis: This is a cluster randomized controlled trial with blinded outcome assessment. The study population is healthcare professionals looking after people with HD in individual RCF in the state of New South Wales. Each RCF will be centrally randomized to the REAP-HD program or the comparator, SSE. Blinded outcome assessment will be performed by examining drug charts, and using the Neuropsychiatric Inventory-Q (NPI-Q). Primary outcome is the proportion of people with HD who has had a reduction in antipsychotic use, 4 months after the intervention. Secondary outcome measures are: 1) change in severity of behavioral symptoms, as measured by the NPI-Q at 4 months (to ensure antipsychotic reduction has not lead to worsening behavioural symptoms); and 2) proportion of people with HD who has had a reduction in antipsychotic dosage at 4 months for each strategy, compared with 4 months prior to enrolment (to capture the possibility that both arms reduced antipsychotic use). Analysis will be by intention-to-treat, and take into account the clustering. This is an ongoing trial. Trial protocol and preliminary data on participant characteristics will be presented. Trial registration: ACTRN12614000083695. Funding: NHMRC TRIP Fellowship APP1035429. Huntington disease (HD) is a severe neurodegenerative disorder characterized by a variable clinical profile. In addition to the classic symptoms, HD is complicated by non-neurological features, including weight loss. Despite adequate food intake, HD patients can experience progressive weight loss, which is reported to represent an important hallmark of the disease that might influence patients' quality of life. To date, many are the hypotheses that have been postulated to possibly explain such a phenomenon; however, none of them is conclusive. The main aim of this study was to explore whether compromised gastrointestinal (GI) function might represent the pathophysiologic event leading to body weight loss both in animal models and in patients with HD, and to clarify the underlying molecular mechanism. Standard histopathological analyses were carried out on symptomatic HD R6/2 mouse-derived intestinal tract, as well as on HD patient-derived intestinal biopsy and controls. Semiquantitative analysis of villus length and mucosal thickness was performed after hematoxylin and eosin staining. In line with previous studies, our data demonstrate that symptomatic R6/2 mice display remarkable morphological alterations in the GI tract as the disease progresses. Importantly, preliminary data highlight similar results also in a HD patient-derived intestinal tissue, where the average length of the villi, as well as mucosal thickness, was markedly reduced when compared with healthy control. To our best knowledge, this is the first evidence showing anatomical abnormalities of the GI tract in HD patients. This finding prompts us to hypothesize that HD related-dysfunctions may significantly influence functional integrity of the GI tract, induce malabsorption, and ultimately contribute to the body weight loss. Although the molecular basis of such alteration remains to be investigated, our study discloses an additional peripheral dysfunction with a potential clinical relevance pointing toward novel therapeutic targets in HD.
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Memory for the temporal order of items or events in a sequence has been shown to be impaired in those with manifest Huntington disease (HD) and premanifiest gene carriers for HD. The present study examined the effects of interference on memory for sequences of visuospatial stimuli during the premanifest and manifest stages of HD. Individuals diagnosed with HD, premanifest gene carriers for HD, and healthy controls completed a visuospatial temporal order memory task involving manipulations of the temporal separation between 2 spatial locations in a sequence. During the sample phase, participants viewed a series of 8 circles appearing in different spatial locations on a computer screen in a random sequence that varied on each trial. During the choice phase, participants were shown 2 circles from the prior sequence and were asked which occurred earliest in the sequence. Temporal separations of 0, 2, 4, and 6 lags represented the number of circles that occurred between the 2 choice phase circles in the sample phase sequence. Smaller temporal lags were hypothesized to result in greater interference compared with larger temporal lags. Premanifest gene carriers were significantly impaired (p <0.05) compared with controls on proximal temporal separations (0 and 2 lags) but improved and matched controls on distal separations (4 and 6 lags). The HD group was significantly impaired (p<0.05) relative to controls on all temporal separation lags, but improved as a function of increased temporal separation. The findings suggest that premanifest gene carriers demonstrate temporal order memory impairment in situations when interference is high. In addition, the data indicate that temporal order memory is impaired in manifest HD even when temporal interference is minimal. The findings identify a fundamental, yet relatively unexamined, processing deficit that may affect multiple cognitive functions and the execution of various daily living skills in individuals with HD.
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Differential Visuospatial Impairment During the Premanifest and Manifest Stages of Huntington Disease: Evidence From The Visual Spatial Learning Test
L. Rotblatt
While there is evidence to suggest that visuospatial memory is impaired in the manifest stages of Huntington disease (HD), little is known about visuospatial memory in gene carriers prior to phenoconversion. Visuospatial memory was assessed in individuals diagnosed with mild-to-moderate HD, premanifest gene carriers for HD (Pre-HD), and controls using the Visual Spatial Learning Test (VSLT). The VSLT is a standardized measure with evidence for validity and published norms. The test requires marginal fine motor dexterity and uses abstract visual stimuli that are difficult to verbalize. The VSLT assesses immediate and delayed memory for designs, the positions of designs, and design/position associations. Performance on the VSLT for the HD group was significantly impaired (p <0.05) relative to the control and Pre-HD groups on both immediate and delayed memory for designs, positions, and design/position associations. The Pre-HD group was significantly impaired (p <0.05) relative to controls on immediate and delayed memory for design/position associations. However, there were no significant differences observed between the Pre-HD and control groups on immediate or delayed memory for designs or positions. Thus, individuals with HD show significant impairments on all measures of the VSLT. However, premanifest gene carriers only show deficits relative to controls on memory for object-place associations. The results offer a novel insight into a relatively unexamined memory deficit that may occur in gene carriers for HD prior to phenoconversion. The results also indicate that the VSLT is a useful measure of visuospatial memory during the premanifest and manifest stages of HD.
and HDYO has 7000 social media fans. In January 2014, HDYO launched the first youth services project in the United States Mid-Atlantic Region. The youth service has been up and running for approximately 7 months and accepting referrals for 4 months. There are currently 11 families connected to the project (19 young people) and the youth worker has interacted with another 15 throughout the US via the HDYO website. The youth worker has attended 15 HD Clinics, 7 support groups, 9 different HD events, and held 5 family visits outside of the clinics and support groups. HDYO provides an important service for the HD community worldwide.
